Skip to main content

Table 3 Treatment outcome according to tumor characteristics in 84 patients with basal cell carcinoma treated by electrochemotherapy

From: Basal cell carcinoma: 10-year experience with electrochemotherapy

Variable

Response rate, n (%)

p

CR rate

n (%)

p

LPFS (mos), median (range)

p

5-year recurrence rate,  %

Age at first ECT

 

0.756

 

0.048

 

0.077

 

 ≤69 (n = 42)

37 (88.1%)

27 (64.3%)

35.0 (2.2–120.1)

–

 ≥70 (n = 42)

35 (83.3%)

15 (35.7%)

23.3 (3.6–114.8)

 

PS (ECOG)

 

0.760

 

0.512

 

0.134

 

 0–1 (n = 40)

35 (87.5%)

18 (45%)

39.7 (2.2–120.1)

–

 2–3 (n = 44)

37 (84.1%)

24 (54.5%)

24.7 (6.8–114.5)

 

No of comorbidities

 

1

 

0.826

 

0.183

 

 0–2 (n = 46)

39 (84.8%)

24 (52.2%)

39.0 (2.2–114.8)

–

 3–6 (n = 38)

33 (86.8%)

18 (47.4%)

27.2 (2.2–120.1)

 

Presentation

 

0.244

 

0.004

 

0.141

 

 Primary (n = 42)

38 (90.5)

28 (66.7)

34.2 (2.2–118.4)

–

 Recurrent (n = 42)

34 (80.9)

14 (33.3)

29.1 (3.5–113.1)

 

BCC extent

 

0.001

 

<0.001

 

<0.001

 

 Local (n = 40)

39 (97.5)

29 (72.5)

38.9 (2.2–110.0)

20

 Locally-adv (n = 41)

32 (78.0)

13 (31.7)

23.0 (3.5–118.4)

38

Aggressive histology

 

0.006

 

0.046

 

0.016

 

 Yes (n = 15)

9 (60)

4 (26.7)

21 (3.5–107.9)

52

 No (n = 69)

63 (91.3)

38 (55.1)

33·7 (4.7–118.4)

24

T size

 

<0.001

 

<0.001

 

<0.001

 

 ≤3 cm (n = 52)

52 (100)

36 (69.2)

44.3 (2.2–118.4)

20

 >3 cm (n = 32)

20 (62.5)

6 (18.7)

11.5 (3.5–112.5)

58

Ill-defined borders

 

<0.001

 

0.021

 

<0.001

 

 Yes (n = 20)

12 (60)

5 (25)

11.2 (3.5–107.9)

68

 No (n = 64)

60 (93·7)

37 (57.8)

40.75 (2.2–118.4)

22

Location riska

 

0.728

 

0.436

 

0.212

 

 Low (n = 32)

29 (90.6)

19 (59.4)

31 (15.5–118.4)

–

 Intermediate (n = 33)

26 (78.8)

14 (42.4)

21.0 (4.7–107.9)

 

 High (n = 19)

17 (89.5)

9 (47.4)

48.7 (6.7–75.3)

 

Ulceration

 

0.005

 

0.001

 

<0.001

 

 Yes (n = 42)

31 (73.8)

13 (30.9)

21.3 (3.5–118.4)

52

 No (n = 42)

41 (97.6)

29 (69)

43.0 (2.2–113.1)

12

TNM

 

<0.001

 

<0.001

 

0.174 

 

 T1 (n = 32)

32 (100)

26 (81.2)

41.5 (2.2–113.1)

–

 T2 (n = 50)

40 (80)

16 (32)

22.9 (3.5–118.4)

 

 T3 (n = 2)

0 (0)

0 (0)

7.0 (6.8–7.3)

 

BLM route

 

0.002

 

0.005

 

0.007

 

 i.t. (n = 51)

49 (96.1)

32 (62.7)

41.7 (2.2–118.4)

–

 i.v. (n = 33)

23 (69.7)

10 (30.3)

14.5 (3.5–112.5)

 

Electrode

 

0.05

 

0.027

 

0.423 

 

 Finger (n = 12)

12 (100)

9 (75)

41.5 (17.3–87.9)

–

 Linear (n = 46)

41 (89.1)

25 (54.3)

26.8 (2.2–118.4)

 

 Hexagonal (n = 26)

19 (73.1)

8 (30.8)

20.6 (3.5–113.1)

  
  1. Italic values indicate significance of p value (p < 0.05)
  2. CR complete response, LPFS local progression-free survival, mos months, PS performance status, ECOG Eastern Cooperative Oncology Group, BCC basal cell carcinoma, adv advanced, BLM bleomycin
  3. aLow risk locations: trunk and extremities; intermediate risk locations: cheeks, forehead, scalp, neck; high risk locations: central face, eyelids, peri-orbital, nose, lips, chin, mandible, ear, pre-/post-auricular, genitalia, hands and feet
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us